



US00D941918S

(12) **United States Design Patent**
Krause et al.

(10) **Patent No.:** **US D941,918 S**
(45) **Date of Patent:** **** Jan. 25, 2022**

(54) **CARD**

2033/10; B42D 2033/18; B42D 2033/20;
B42D 2033/22; B42D 2033/28; G09F
3/02; G09F 2003/0201

(71) Applicant: **GENOMIND**, King of Prussia, PA
(US)

See application file for complete search history.

(72) Inventors: **David S. Krause**, King of Prussia, PA
(US); **Daniel Dowd**, King of Prussia,
PA (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignee: **GENOMIND, INC.**, King of Prussia,
PA (US)

D453,529 S * 2/2002 Roth D19/10
D669,932 S * 10/2012 Allen D19/10
D900,927 S * 11/2020 Kurani D19/9

(**) Term: **15 Years**

* cited by examiner

(21) Appl. No.: **29/721,517**

Primary Examiner — Abraham Bahta

(22) Filed: **Jan. 21, 2020**

(74) *Attorney, Agent, or Firm* — Morgan, Lewis &
Bockius LLP; Brett A. Lovejoy

(51) **LOC (13) Cl.** **19-08**

(52) **U.S. Cl.**

(57) **CLAIM**

USPC **D19/9**

The ornamental design for a card, as shown and described.

(58) **Field of Classification Search**

DESCRIPTION

USPC D19/1-12, 20-34, 100;
40/124.01-124.15, 672, 661, 726, 776,
40/617; 283/72, 74-75, 103, 105-117,
283/82, 70, 94, 81; 206/449; D21/385;
D20/10, 22, 27, 40, 42, 11;
D14/435-437; 235/380, 382, 487, 493,
235/488; D6/613, 583; 360/2; 702/158,
702/86, 97, 163, 166, 170
CPC B42D 15/00; B42D 15/022; B42D 15/027;
B42D 15/042; B42D 15/045; B42D
25/00; B42D 25/20; B42D 25/30; B42D
25/23; B42D 25/26; B42D 25/29; B42D
25/285; B42D 2033/00; B42D 2033/02;
B42D 2033/04; B42D 2033/08; B42D

FIG. 1 is a front view of the card showing our new design;
and,
FIG. 2 is a back view thereof.
The hatching shown in the Figures indicates a contrast in
appearance, where the contrast is a different pattern or a
different color than the non-stippled portions of the card.
The broken lines showing elements in the above described
Figures are for illustrative purposes only and form no part of
the claimed design.
The card has no appreciable thickness.

1 Claim, 2 Drawing Sheets

GENOMIND PROFESSIONAL PHARM		Example Patient	
RxMetaType™ Card		#234567890	
Gene	Genotype	Phenotype	Clinical Meaning*
CYP1A2	*1F/*1F	Extensive	Normal Metabolism, but ↑ metabolism in smokers
CYP2E6	*1/*1	Extensive	Normal Metabolism
CYP2C19	*1/*1	Extensive	Normal Metabolism
CYP2C9	*1/*3	Intermediate	↓ Metabolism of some drugs
CYP2D6	*4/*4	Poor	↓ Metabolism of some drugs
CYP3A4/5	*2B/*3B	Normal	Normal Metabolism


		Example Patient	
RxMetaType™ Card		#1234567890	
Gene	Genotype	Phenotype	Clinical Meaning*
CYP1A2	*1F/*1F	Extensive	Normal Metabolism, but ↑ metabolism in smokers
CYP2B6	*1/*1	Extensive	Normal Metabolism
CYP2C19	*1/*1	Extensive	Normal Metabolism
CYP2C9	*1/*3	Intermediate	↓ Metabolism of some drugs
CYP2D6	*4/*4	Poor	↓ Metabolism of some drugs
CYP3A4/5	*1/*1 *3/*3	Normal	Normal Metabolism

Figure 1



Issued Date: dd/mm/yyyy

FOR USE BY HEALTHCARE PROFESSIONALS ONLY

Most medicines are metabolized by liver enzymes. Like blood types, you have a specific genetic profile which can affect the rate of metabolism, and may influence the dose of medicines prescribed for you. You may wish to inform your healthcare provider(s) about your metabolism status, shown on the reverse. More information about specific gene/drug interactions can be found at:

<http://drug-interactions.medicine.u.edu/Clinical-Table.aspx>

<http://www.pharmgkb.org/guidelines>

<http://www.fda.gov/media/124784/download>

*Do not discontinue or change the dose of any medicine without the advice of your healthcare provider. In addition to genetics, other factors may influence your metabolizer status.

Figure 2